[Click eStock] "Yuhan Yanghaeng, Growing Expectations for Reklaza Approval"

Meritz Securities analyzed on the 11th that momentum is building ahead of the approval of Reklaza for Yuhan Corporation.

Junyoung Kim, a researcher at Meritz Securities, stated in a report on the same day, “As the PDUFA date for the Reklaza/Librivant combination therapy approaches, Yuhan Corporation's stock price is rising,” and added, “Since the competing drug Tagrisso/chemotherapy combination therapy was approved two months ahead of its PDUFA date, Reklaza is also likely to be approved before the PDUFA deadline.”

He also mentioned, “Following approval, there is an expectation of improved operating profit due to milestone payments, along with momentum from the announcement of the final OS data from the MARIPOSA Phase 3 clinical trial in 2025 and the approval of the Reklaza/Librivant SC (subcutaneous injection) combination therapy.”

Furthermore, he explained, “On the 20th of last month, Gilead announced the early termination of the Phase 3 blinded trial for the twice-yearly HIV prevention drug Lenacapavir, along with a 100% HIV prevention efficacy. Despite the high efficacy of existing oral prevention drugs, their daily dosing requirement has limited their expected effectiveness, so sales growth of Lenacapavir is anticipated.”

He added, “Currently, Yuhan Chemical has been identified as one of the raw material suppliers, and with the completion of the factory expansion, there is potential for additional orders.”